CellCentric closes first tranche of series B financing

Posted on March 14th 2011

New funding sees CellCentric expand drug discovery activities across multiple epigenetic targets.

CellCentric, the biotechnology company focused on epigenetics, has closed further investment funding, the two main contributors being Morningside Venture Investments and Takeda Venture Investments. The company is progressing small molecule inhibitors against histone demethylase, histone methyltransferase and ubiquitin related targets.

The company has a competitive advantage gained through a differentiated business model based on intellectual property relationships with multiple world leading academic researchers in epigenetics. This not only aids CellCentric in identifying and prioritising targets, but supports the company through the drug discovery process. The company is primarily focused on novel cancer therapeutics, however epigenetic target inhibitors may have relevance for other indications including immune-inflammatory diseases, neurodegenerative conditions and metabolic disorders.